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In Brief
The tuberous sclerosis proteins TSC1 and
TSC2 together inhibit mTOR-dependent
growth and proliferation. Thien, Prentzell
et al. show that TSC1, independently of
TSC2, couples TGF-b-Smad2/3-
dependent growth arrest and epithelial-
to-mesenchymal transition to insulin-Akt
signaling. This crosstalk may allow
rescue of cellular overgrowth in contexts
of aberrant Akt activity.
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The tuberous sclerosis proteins TSC1 and TSC2
are key integrators of growth factor signaling. They
suppress cell growth and proliferation by acting in a
heteromeric complex to inhibit the mammalian target
of rapamycin complex 1 (mTORC1). In this study, we
identify TSC1 as a component of the transforming
growth factor b (TGF-b)-Smad2/3 pathway. Here,
TSC1 functions independently of TSC2. TSC1 inter-
acts with the TGF-b receptor complex and Smad2/3
and is required for their association with one another.
TSC1 regulates TGF-b-induced Smad2/3 phosphory-
lation and target gene expression and controls TGF-
b-induced growth arrest and epithelial-to-mesen-
chymal transition (EMT). Hyperactive Akt specifically
activates TSC1-dependent cytostatic Smad signaling
to induce growth arrest. Thus, TSC1 couples Akt ac-
tivity to TGF-b-Smad2/3 signaling. This has implica-
tions for cancer treatments targeting phosphoinosi-
tide 3-kinases and Akt because they may impair
tumor-suppressive cytostatic TGF-b signaling by in-
hibiting Akt- and TSC1-dependent Smad activation.
INTRODUCTION
Transforming growth factor b (TGF-b) signaling has emerged as
a major regulator of development, tissue homeostasis, and dis-Develease. Mutations in TGF-b pathway components cause develop-
mental defects, and perturbations in TGF-b signaling in the adult
are linked to tumorigenesis and metastasis (Meulmeester and
Ten Dijke, 2011). The TGF-b ligand signals through a hetero-
tetrameric TGF-b receptor type I (TbR-I)-TGF-b receptor type II
(TbR-II) complex that phosphorylates the Smad2 and Smad3
proteins within their C-terminal SSXS serine motifs. Phospho-
activated Smad2/3 form a complex with Smad4 that accumu-
lates in the nucleus and regulates numerous target genes.
Depending on the cellular context, these transcriptional events
induce growth arrest and apoptosis, but also EMT, cell migration
and invasiveness (Massague´, 2012). The versatility of TGF-b
signaling underlies its multifaceted role in cancer, frequently
switching from tumor-suppressive to tumor-promoting functions
in the course of tumor development (Tian and Schiemann, 2009).
Increasing evidence suggests that both cytostatic andpro-met-
astatic actions of canonical TGF-b-Smad2/3 signaling are modu-
lated by components of the phosphoinositide 3-kinase (PI3K),
Akt, and mammalian target of rapamycin complex 1 (mTORC1)
pathway, thus linking mitogenic growth factor signaling to the
TGF-b pathway (Bakin et al., 2000; Birchenall-Roberts et al.,
2004; Conery et al., 2004; Remy et al., 2004; Song et al., 2006;
Xue et al., 2012; Zhanget al., 2012). The tuberous sclerosis protein
(TSC) TSC1-TSC2 complex is negatively regulated by insulin/IGF-
1-PI3K-Akt signaling. TSC1-TSC2 suppresses the activity of the
mTORC1 multiprotein complex (comprising mTOR kinase and
thecore scaffoldproteinRaptor) through inhibitionof themTORC1
activator Ras homolog enriched in brain (Rheb) (Orlova and Crino,
2010). Active mTORC1 phosphorylates its targets ribosomal
protein S6 kinase (p70-S6K) and eukaryotic translation initiation
factor 4E binding protein 1 (4E-BP1) to control cellular growthopmental Cell 32, 617–630, March 9, 2015 ª2015 Elsevier Inc. 617
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Figure 1. TSC1 Regulates TGF-b-Smad2/3 Signaling
(A) TSC1, but not TSC2, is required for TGF-b1-induced phosphorylation of Smad2/3. Inducible HeLa shRNA cell lines were treated with doxycycline to induce
shRNA expression, or left untreated. Cells were starved and stimulated with TGF-b1 (5 ng/ml; this concentration was used in all experiments if not indicated
otherwise) for 45 min as indicated. Please note that the Smad3-pS423/425 antibody occasionally detected a double band. For these cases, the signal corre-
sponding to the molecular weight of Smad3 of 48 kDa (UniProt Consortium (2014), P84022-1) is marked by an arrow.
(B) Quantitation of three independent experiments as performed in (A); pSmad/total Smad in HeLa shRNA cells; one-way ANOVA, mean values ± SEM; **p < 0.01;
*p < 0.05.
(C) Reduced Smad2/3 phosphorylation by independent second TSC1-i shRNA sequence (TSC1-i #2) upon TGF-b1 treatment. HeLa shRNA cells were starved
and stimulated with TGF-b1 as indicated.
(D) Second independent knockdown of TSC2 (TSC2-i #2) does not affect TGF-b1-induced Smad2/3 phosphorylation. HeLa shRNA cells were starved and
stimulated with TGF-b1 as indicated.
(E) TSC1 deficiency does not affect BMP4 signaling. HeLa shRNA cells were starved and stimulated with BMP4 for 30 min as indicated.
(legend continued on next page)
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and proliferation (Laplante and Sabatini, 2012; Shimobayashi and
Hall, 2014). Of note, mTORC1 and phospho-activated p70-S6K
induce a negative feedback loop (NFL), which inhibits upstream
PI3K/Akt activity (Hsu et al., 2011; Sengupta et al., 2010; Yu
et al., 2011). In humans, disintegration of the TSC1-TSC2 com-
plex, bymutations ineither theTSC1orTSC2gene, leads to tuber-
ous sclerosis complex, a multiorgan disease of benign tumors
(Inoki and Guan, 2009). A function of TSC1-TSC2 in linking the in-
sulin- andTGF-bpathwayshas so far not beenaddressed, leaving
the role of the TSCs in TGF-b signaling ill-defined.
RESULTS
TSC1 Is Required for TGF-b1-Induced Smad2/3
Phosphorylation, Nuclear Localization, and Target Gene
Expression
To evaluate the roles of TSC1 and TSC2 in TGF-b signaling, we
individually knocked down either TSC1 or TSC2 in HeLa cells
by inducible shRNA expression (TSC1-i, TSC2-i). Expectedly,
activation of the TGF-b-Smad2/3 pathway by TGF-b1 treatment
resulted in phosphorylation of the SSXS motifs of Smad2 (S465/
467) and Smad3 (S423/425) (pSmad2 and pSmad3) in control
knockdown (Ctrl-i) cells (Figure 1A). Knockdown of either TSC1
or TSC2 strongly induced phosphorylation of p70-S6K at T389,
due to derepression of mTORC1. Surprisingly, we observed
that TSC1 but not TSC2 deficiency severely impaired Smad2
and Smad3 phosphorylation in response to TGF-b1 stimulation
(Figure 1A). The ratio of pSmad2/total Smad2 and pSmad3/total
Smad3 was significantly reduced by TSC1 deficiency, whereas
it remained unchanged by TSC2 knockdown (Figure 1B). The
pSmad inhibition observed in the TSC1 knockdown cell line
TSC1-i #1 upon short-term TGF-b1 treatment (Figure 1A) was
confirmed by a second shRNA sequence targeting TSC1 in a
different exon (TSC1-i #2, Figure 1C). Also, after long-term
TGF-b1 stimulation (24 and 48 hr), TSC1 knockdown by both
sequences, TSC1-i #1 or TSC1-i #2, inhibited Smad phosphory-
lation (Figure S1A). Moreover, expression of a mutagenized
TSC1-myc construct (TSC1-mycnon-targeted), which is not tar-
geted by TSC1-i #1 knockdown (Figure S1B), rescued Smad2/
3 phosphorylation in TSC1-i #1 knockdown cells (Figure S1C),
further validating that TSC1 is required for Smad2/3 phosphory-
lation. Targeting TSC2 with an independent second shRNA
sequence (TSC2-i #2, Figure 1D) did not show any effect on
Smad phosphorylation. Consistent with these results obtained
in HeLa epithelial cells, TSC1, but not TSC2, deficiencymitigated
TGF-b1-induced Smad2/3 phosphorylation also in HEK293T
cells (Figure S1D), indicating that TSC1 is a crucial component
of TGF-b signaling in different cellular contexts. Notably, we
found that BMP4 triggered phosphorylation of Smad1/5/8 was(F) Nuclear enrichment of Smad2/3 is impaired under TSC1 deficiency. Confocal
starved, pretreated with the TbR-I inhibitor SB431542 (10 mM; 1 hr prior to TGF-
antibody. Insert: A detailed view of an individual cell. Scale bar represents 10 mm
(G) Quantitation of three independent experiments as performed in (F); percenta
values from three independent experiments with at least five independent fields o
values ± SD; ***p < 0.001.
(H) TSC1, but not TSC2, is required for TGF-b1-induced expression of p21. HeL
Immunoblot (IB) analysis of cell lysates (A, C, D, E, and H). ns, not statistically si
See also Figure S1.
Develnot affected by TSC1 deficiency (Figure 1E), suggesting that
TSC1 specifically regulates Smad2/3 signaling. Previous studies
have shown that TGF-b activates mTORC1 and p70-S6K via the
PI3K-Akt-TSC1/2 axis in a cell-type-specific manner (Das et al.,
2008; Kato et al., 2009; Lamouille and Derynck, 2007; Rahimi
et al., 2009; Wu and Derynck, 2009) (see Figure S1D; please
note that TGF-b1 does not induce p70-S6K-pT389 in epithelial
HeLa cells, Figure 1A). Our results suggest that TSC1 is not
only involved in TGF-b-dependent mTORC1 regulation, but
also affects TGF-b-Smad signaling itself.
In keeping with the reduced Smad2/3 phosphorylation, nu-
clear Smad2/3 accumulation upon TGF-b1 stimulation was
also decreased in HeLa TSC1-i cells, but not in TSC2-i cells
(Figures 1F and 1G). This further corroborates a regulatory func-
tion of TSC1 toward Smad2/3. TGF-b-Smad signaling causes
growth arrest in epithelial, neural, and hematopoietic cells by
repressing mitogenic and inducing cytostatic target genes (Hel-
din et al., 2009), including the cyclin-dependent kinase inhibitors
p21 and p57Kip2 (Lee et al., 2004, 2007; Nishimori et al., 2001;
Pardali et al., 2005; Scandura et al., 2004). We found that
TSC1, but not TSC2, knockdown suppressed the TGF-b1-
dependent increase in p21 (Figure 1H) and p57Kip2 levels (Fig-
ures S1E and S1F). Thus, TSC1 positively controls Smad2/3
phosphorylation and nuclear translocation, and cytostatic TGF-
b target gene expression.
TSC1 Regulates Smad2/3 Phosphorylation
Independently of the TSC1-TSC2 Effectors Rheb and
mTORC1
Because TSC1 deficiency, via suppression of TSC1-TSC2 com-
plex activity, stimulates Rheb and mTORC1, we tested whether
mTORC1 activity contributes to the regulation of Smad2/3 phos-
phorylation by TSC1. Inhibition of mTORC1 by rapamycin or
PP242 efficiently suppressed aberrant mTORC1 activation in
TSC1 knockdown cells as monitored by p70-S6K phosphoryla-
tion (Figure 2A). Yet, mTORC1 inhibition did not restore deficient
Smad2/3 phosphorylation (Figures 2A and 2B). Also, several ap-
proaches to inhibit mTORC1 activity (rapamycin, PP242, shRNA
targeting Raptor; Figure 2C), or Rheb (Figures 2D and 2E) in
TSC1-positive cells did not affect TGF-b1-induced Smad2/3
phosphorylation. Thus, TSC1 regulates Smad2/3 phosphoryla-
tion independently of the canonical TSC1-TSC2 effectors Rheb
and mTORC1.
TSC1 Interacts with TbR-I/II and Smad2/3 and Is
Required for TGF-b1-Induced TbR-I-Smad2/3
Association
To explore the mechanisms via which TSC1 regulates Smad2/3
phospho-activation, we tested whether TSC1 knockdownimmunofluorescence (IF) microscopy images of HeLa shRNA cells. Cells were
b1), and stimulated with TGF-b1 (1 hr) as indicated. IF stainings with Smad2/3
.
ge of cells with predominantly nuclear staining of Smad2/3; shown are mean
f view per experimental condition of each experiment; one-way ANOVA, mean
a shRNA cells were stimulated with TGF-b1 for 48 hr as indicated.
gnificant.
opmental Cell 32, 617–630, March 9, 2015 ª2015 Elsevier Inc. 619
A B
C
D
E
Figure 2. TSC1-Dependent Phospho-Smad2/3 Regulation Does Not Involve mTORC1
(A) Impaired Smad activation by TGF-b1 in TSC1 knockdown is not restored bymTORC1 inhibition. HeLa shRNA cells were starved and pretreatedwith themTOR
inhibitors PP242 (200 nM) or rapamycin (200 nM) for 1 hr prior to TGF-b1 stimulation (45 min) as indicated.
(B) Quantitation of three independent experiments as performed in (A); pSmad/total Smad in HeLa shRNA cells; one-way ANOVA, mean values ± SEM.
(C) HeLa shRNA cells were cultivated in full medium and pretreated with PP242 (200 nM) or rapamycin (200 nM) for 1 hr prior to TGF-b1 stimulation as indicated.
(D) HeLa Rheb-i #1 and Rheb-i #2 shRNA cells were cultivated in full medium and stimulated with TGF-b1 as indicated.
(E) Quantitation of three independent experiments as performed in (D); pSmad/total Smad in HeLa shRNA cells, 45 min TGF-b1; one-way ANOVA, mean
values ± SEM.
IB analysis of cell lysates (A, C, and D). ns, not statistically significant.reduces TGF-b receptor protein levels or alters levels of major
TGF-b pathway modulators. TSC1 knockdown did not downre-
gulate TbR-I or TbR-II levels (Figure S2A). Furthermore, TSC1
deficiency did not result in reduced levels of the positive modu-
lator Smad anchor for receptor activation (SARA), which facili-
tates Smad phosphorylation, or increased levels of the inhibitory
modulator Smad7 (Figure S2A).
We next hypothesized that TSC1 may modulate Smad2/3
phosphorylation by associating with Smad2/3 or the TGF-b
receptor proteins. We assessed endogenous TSC1-Smad2/3
association by proximity ligation assay (PLA), which due to its
high sensitivity is a valuable tool to monitor transient and dy-
namic protein associations in situ (So¨derberg et al., 2008), and
found that TSC1 associates with Smad2/3 upon TGF-b1 treat-
ment (Figures 3A and 3B; negative controls in Figure 3C).
To test if TSC1 forms physical complexes with the Smad pro-620 Developmental Cell 32, 617–630, March 9, 2015 ª2015 Elsevierteins, we performed co-immunoprecipitations. Indeed, TSC1-
myc co-precipitated with both Flag-Smad2 and Flag-Smad3
(Figure S2B, negative control in Figure S2C). Mapping experi-
ments with TSC1 truncation constructs (Hoogeveen-Westerveld
et al., 2010) revealed that TSC1-Smad3 binding requires the
N-terminal part of TSC1 (Figure S2D), which contains a putative
transmembrane domain (amino acids 127–144) (van Slegten-
horst et al., 1997). Interestingly, TSC1-Smad3 interaction did
not require the C-terminal coiled-coiled domain of TSC1 (amino
acids 721–997) (UniProt Consortium, 2014; http://www.uniprot.
org/uniprot/Q92574) (Figure S2D), which is involved in mediating
TSC1-TSC2 interaction (Hoogeveen-Westerveld et al., 2010).
This indicates that distinct TSC1 domains mediate TSC1-Smad
and TSC1-TSC2 interactions, respectively. Furthermore, TSC1
co-precipitated with both TbR-I (Figure 3D; PLA of TSC1-TbR-I
association in Figure S2E) and TbR-II (Figure S2F). TSC2 didInc.
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Figure 3. TSC1 Mediates TGF-b1-Induced TbR-I-Smad2/3 Association
(A and B) Analysis of endogenous TSC1-Smad2/3 association by proximity ligation assay (PLA). HeLa shRNA cells were starved and stimulated with TGF-b1 for
10 min as indicated. Confocal images (A) and quantitation (B) of PLAs. Red dots represent protein interaction events; DAPI nuclear staining in blue (this applies
also for the following PLA data). (B) Area of interaction in square pixels. One-way ANOVA, mean values ± SD; ***p < 0.001; ns = not statistically significant.
(C) Negative control of PLA experiment depicted in (A). Confocal images of PLA performed with single primary antibodies, followed by incubation with both oligo-
linked secondary antibodies (this applies also for the following PLA negative controls).
(D) TSC1, but not TSC2, interacts with TbR-I. Immunoprecipitation (IP) from lysates of Flag-TSC1 or Flag-TSC2 transfected HeLa cells was performed using either
TbR-I-specific or control rabbit IgG antibodies (mock).
(E) TSC1 is required for endogenous TbR-I-Smad2/3 association in response to TGF-b1. HeLa shRNA cells were starved and stimulated for 2 to 20 min with TGF-
b1 as indicated. Confocal images of PLAs.
(F) Negative control of PLA experiment depicted in (E).
Scale bar (A, C, E, and F) represents 10 mm.
See also Figure S2.not interact with TbR-I (Figure 3D) and TSC1 remained bound to
TbR-I in TSC2 knockdown cells (Figure S2G), further supporting
a TSC2-independent role of TSC1 in the TGF-b pathway.
TSC1’s interaction with TbR-I and Smad2/3 suggested that
TSC1 regulates TbR-I-Smad2/3 association. We assessed this
possibility by PLA. TGF-b1 treatment induced a strong and tran-Develsient association of endogenous TbR-I-Smad2/3 in Ctrl-i cells
at approximately 10 min of TGF-b1 stimulation (Figure 3E; nega-
tive controls in Figure 3F). TSC1 deficiency impaired TGF-b1-
induced TbR-I-Smad2/3 binding, revealing a role for TSC1 in
mediating the association of TbR-I with its substrates (Figure 3E).
Interestingly, we observed TbR-I-Smad2/3 association also atopmental Cell 32, 617–630, March 9, 2015 ª2015 Elsevier Inc. 621
later time points of TGF-b1 stimulation (Figure S2H; 40 min TGF-
b1), indicating that multiple peaks of TSC1-dependent TbR-I-
Smad2/3 association contribute to Smad2/3 phosphorylation.
TSC1 Links Active Insulin-PI3K-Akt Signaling to the
TGF-b-Smad2/3 Pathway
We next tested if insulin/IGF-1-PI3K-Akt signaling, which re-
gulates TSC1-TSC2 activity toward mTORC1, also affects
TSC1’s function in the TGF-b pathway. Indeed, constitutively
active myristoylated Akt (myr-Akt) strongly promoted TSC1-
TbR-I (Figures 4A and 4B; negative control in Figure 4C), and
TbR-I-Smad2/3 association (Figures 4D and 4E; negative control
in Figure 4F). As previously reported,myr-Akt reduced TSC2pro-
tein levels (Figure S3A) (Dan et al., 2002; Plas and Thompson,
2003) and decreased TSC1-TSC2 interaction (Figure S3B) (Inoki
et al., 2002; Potter et al., 2002), confirming the functionality of
myr-Akt in TSC1-TSC2 complex regulation. In line with its stimu-
lating effect on TbR-I-Smad2/3 association (Figures 4D and 4E),
myr-Akt expression enhanced Smad2/3 phosphorylation in
a dose-dependent manner (Figure 4G). Absence of TGF-b1 in
starved cells or treatment with the TbR-I inhibitor SB431542 prior
to TGF-b1 stimulation prevented efficient enhancement of Smad
phosphorylation by myr-Akt (Figure S3C). Hence, myr-Akt-in-
duced Smad phosphorylation requires TbR-I activity. myr-Akt-
induced Smad phospho-activation was inhibited by TSC1
deficiency (Figures 4HandS3D), but not by TSC2deficiency (Fig-
ure 4I) or bymTORC1 inhibition (Figure 4J). Thus, TSC1mediates
Akt-dependent Smad2/3 phospho-activation, independently of
its function in the TSC1-TSC2 complex. Consistently, insulin
stimulation also enhanced TGF-b1-induced Smad2/3 phosphor-
ylation (Figure 4K), which was abolished in TSC1-deficient cells
(Figure 4L). Furthermore, overexpression of phosphatase and
tensin homolog (PTEN), a PI3K antagonist that counteracts Akt
activation, inhibited pSmad2/3 (Figure S3E). Thus, TSC1 links in-
sulin-PI3K-Akt signaling to TGF-b-Smad2/3 pathway activation.
To test if insulin-induced Smad2/3 phospho-activation in-
volves mTORC1, insulin and TGF-b1 stimulation were combined
with mTORC1 inhibition. Of note, enhanced Smad2/3 phosphor-
ylation upon insulin treatment was even further increased in
Raptor knockdown cells (Figure S3F). Inactivation of Raptor at-
tenuates the mTORC1-dependent NFL, resulting in enhanced
Akt activation. Thus, increased Smad2/3 phosphorylation in
Raptor deficient cells may be due to Akt activation caused by
NFL inhibition. In agreement, we observed strongly enhanced
Akt-pT308 upon insulin stimulation in HeLa Raptor-i cells (Fig-
ure S3F). Complementing these findings, TSC1-myc overex-
pression increased pSmad2/3 under rapamycin-induced Akt
activation (Figure S3G). TSC1-myc expression without Akt acti-
vation did not affect Smad2/3 phosphorylation, consistent with
a stimulatory function of Akt upstream of TSC1 in Smad2/3 regu-
lation. This suggests that changes in mTORC1 activity, via the
NFL, can indirectly control Smad2/3 phospho-activation when
Akt is activated, e.g., by insulin.
TbR-I-mediated Smad2/3 phospho-activation takes place at
the plasma membrane and in EEA1 positive early endosomes,
containing Smad proteins and the internalized activated TGF-b
receptor complex (Atfi et al., 2007; Chen, 2009; Di Guglielmo
et al., 2003; Hayes et al., 2002; McLean and Di Guglielmo,
2010). Within the mTOR pathway, the TSC1- TSC2 complex622 Developmental Cell 32, 617–630, March 9, 2015 ª2015 Elsevierlocalizes to lysosomes (Demetriades et al., 2014; Dibble et al.,
2012; Menon et al., 2014) and peroxisomes (Zhang et al., 2013)
to regulate the mTOR activator Rheb. Where does TSC1 exert
its TSC2-independent function in TGF-b pathway regulation?
In line with previous studies (Plank et al., 1998; Zhang et al.,
2013), we observed that anti-TSC1 staining yields a punctate
cytoplasmic pattern reminiscent of discrete vesicular structures
(Figure 5A; specificity control for TSC1 antibody in Figure 5B).
Co-staining of TSC1 with the early endosome marker EEA1 re-
vealed an overlap (Figure 5A; negative control in Figure 5C),
quantified by the nonlinear Spearman’s rank correlation coeffi-
cient (rs) (rs = 0.51 ± 0.13 SD). In keeping with the stimulatory in-
sulin-Akt function upstream of TSC1 (Figures 4G, 4H, 4K, and
4L), insulin stimulation, but not TGF-b1, altered the pattern of
TSC1-EEA1 co-localization structures (Figures 5D–5F), and
significantly increased their co-localization (rs starved = 0.36 ±
0.05 SD; rs insulin = 0.49 ± 0.01 SD; rs TGF-b1 = 0.40 ± 0.03 SD;
pstarved versus insulin < 0.01; pstarved versus TGF-b1 > 0.05), without
increasing total TSC1 protein levels (Figure 5G).
TSC1 Is Required for TGF-b1-Induced Growth Arrest
and EMT
TGF-b-Smad signaling is a major regulator of growth arrest and
EMT (Massague´, 2012). Hence, we testedwhether TSC1 and Akt
regulate Smad-dependent features of these processes.We used
epithelial NMuMG cells as a well-established cell model to study
the cellular TGF-b response (Deckers et al., 2006; Lamouille and
Derynck, 2007; Miettinen et al., 1994; Piek et al., 1999; Valcourt
et al., 2005).
TGF-b causes growth arrest in the G1 phase (Bhowmick et al.,
2003; Lamouille and Derynck, 2007; Law et al., 2002; Miettinen
et al., 1994; Shin et al., 2001; Valcourt et al., 2005), and interfer-
ence with Smad signaling, e.g., by Smad4 knockdown, results in
impaired growth arrest (Levy and Hill, 2005; Zhang et al., 1996).
Consistent with earlier reports (Bhowmick et al., 2001; Levy and
Hill, 2005; Zhang et al., 1996), TGF-b1 treatment resulted in an
increased percentage of cells in the G1 phase in NMuMG Ctrl-i
cells (Figures 6A and S4A). This induction of G1 arrest was signif-
icantly reduced in Smad4 knockdown cells (Figures 6A and S4A).
TSC1 deficiency significantly impaired TGF-b1-induced growth
arrest in G1 phase, whereas TSC2 knockdown did not alter
TGF-b1-dependent growth arrest (Figures 6A and S4A). Similar
to our previous findings in HeLa and HEK293T cells, NMuMG
cells displayed reduced TGF-b1-dependent Smad2/3 phos-
phorylation in TSC1, but not in TSC2, knockdown cells (Fig-
ure 6B) and enhanced Smad2/3 phosphorylation upon myr-Akt
expression (Figure 6C), suggesting comparable crosstalk mech-
anisms in NMuMG cells. Consistently, myr-Akt triggered G1 ar-
rest in NMuMG Ctrl-i cells (Figure 6D) and this was suppressed
by Smad4 deficiency (Figure 6D). Taken together, these results
are consistent with a stimulatory function of hyperactive Akt
and TSC1 in cytostatic Smad signaling in NMuMG cells.
Besides its cytostatic action, TGF-b is a crucial inducer of
EMT. EMT is fundamental in organismal development and can-
cer metastasis, and contributes to the tumor-promoting function
of TGF-b signaling in later stages of cancer development (Wendt
et al., 2012). TGF-b-dependent EMT is mediated by Smad and
non-Smad pathways, which control a complex transcriptional
program, ultimately resulting in loss of epithelial markers andInc.
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Figure 4. TSC1 Links Insulin-Akt to TGF-b-Smad2/3 Signaling
(A and B) Constitutively active myristoylated Akt (myr-Akt) enhances TSC1-TbR-I association. HeLa cells were transfected with myr-HA-Akt or empty vector and
stimulated with TGF-b1 for 12.5 min. Confocal images (A), and quantitation (B) of PLAs. Two tailed t test, mean values ± SD; ***p < 0.001.
(C) Negative controls of PLA experiment depicted in (A).
(D and E) myr-Akt enhances TbR-I-Smad2/3 association. Transfection and treatment as performed in (A). Confocal images (D) and quantitation (E) of PLAs. Two
tailed t test, mean values ± SD; *p < 0.05.
(F) Negative controls of PLA experiment depicted in (D).
(G and H) myr-Akt stimulates Smad2/3 phosphorylation (G) and this is TSC1-dependent (H). HeLa cells were transfected with myr-HA-Akt or empty vector (G and
H). Cells were cultivated in full medium (G) or starved and TGF-b1 (15 min) stimulated (H).
(I) HeLa shRNA cells were transfected with myr-HA-Akt or empty vector, starved, and stimulated with TGF-b1 (10 min) as indicated.
(J) myr-HA-Akt or empty vector transfected HeLa cells were treated with PP242 (200 nM) or rapamycin (200 nM) 2 hr prior to lysis as indicated.
(K and L) Insulin enhances TGF-b1-induced Smad2/3 phosphorylation (K) and this is TSC1-dependent (L). HeLa cells were starved and stimulated with insulin
(100 nM, 2 hr) prior to TGF-b1 stimulation (15 min) as indicated.
Scale bar (A, C, D, and F) represents 10 mm. IB analysis of cell lysates (G–L).
See also Figure S3.
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Figure 5. TSC1 Localizes to Early Endosomes
(A) HeLa cells cultivated in full medium were analyzed by IF with anti-TSC1 and anti-EEA1 antibodies. Shown are maximum intensity projections of confocal IF
images. Merged image (right): Yellow regions indicate co-localization/overlay of EEA1 (green) and TSC1 (red); boxes above and right of the merged image show
planes perpendicular to the primary image that were constructed from z stacks (cross in merged image indicates area of z stack, shown as maximum intensity
projection). Inserts (lower): magnified square area; rs, Spearman’s rank correlation coefficient ± SD refers to TSC1-EEA1 co-localization.
(B) Specificity control of TSC1 antibody. HeLa cells were transfected with TSC1-myc and analyzed by IF with anti-TSC1 and anti-myc antibodies. IF images were
taken by wide field microscopy. Merged image (right): Yellow regions indicate overlay of TSC1 (green) and myc (red). Hoechst 33342 nuclear staining in blue.
Scale bar represents 20 mm.
(C) Negative controls of TSC1-EEA1 IF, performedwith IgGmouse and IgG rabbit as primary antibodies.Merged image (right): IgGmouse (red), IgG rabbit (green),
and overlay (yellow). Presentation as in (A).
(D and E) Altered TSC1-EEA1 co-localization in response to insulin. HeLa cells were starved (D) or starved and re-stimulated with insulin (100 nM, 4 hr) (E) as
indicated. IF labeling and presentation as in (A).
(F) HeLa cells were starved as in (D) and stimulated with TGF-b1 (10 min). IF labeling and presentation as in (A).
(G) Total TSC1 protein levels are not induced by insulin. IB analysis of cell lysates. HeLa cells were treated as in (E).
Scale bar (A, C–F) represents 10 mm. Hoe, Hoechst 33342 nuclear staining.
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Figure 6. TSC1 Is Required for TGF-b1-Dependent Growth Arrest and EMT in NMuMG Cells
(A) TSC1 deficiency impairs TGF-b1-induced growth arrest in NMuMG cells. NMuMG shRNA cells were treated with TGF-b1 (24 hr) and subjected to propidium
iodide staining followed by flow cytometry. Quantitation of four independent experiments with each condition being performed in duplicates or triplicates in
each experiment. Results are shown as box plots representing median, 25th and 75th percentiles as boxes, and the range of data as bars; one-way ANOVA,
**p < 0.01.
(B) TSC1 deficiency impairs Smad2/3 phosphorylation in NMuMG cells. Quantitation of three independent experiments showing pSmad/total Smad. NMuMG
shRNA cells were starved and stimulated with TGF-b1 for 30 min; one-way ANOVA, mean values ± SEM; **p < 0.01; *p < 0.05.
(C) myr-HA-Akt or empty vector expressing NMuMG cells were stimulated with TGF-b1 for 15 min as indicated.
(D) myr-Akt induces growth arrest via Smad signaling. Propidium iodide staining as performed in (A) using stably myr-HA-Akt/empty vector expressing NMuMG
shRNA cells. Box plot presentation as in (A); one-way ANOVA, **p < 0.01.
(E) TSC1 is required for expression of mesenchymal marker proteins. NMuMG shRNA cells were subjected to TGF-b1 treatment (72 hr) as indicated.
(F) Wide field fluorescence images of NMuMG shRNA cells, ± TGF-b1 (72 hr). Scale bar represents 30 mm.
(G) Stably myr-HA-Akt/empty vector expressing NMuMG Ctrl-i or Smad4-i cells were treated with TGF-b1 for 48 hr as indicated.
(H) Schematic representation of TSC1 mediated insulin-Akt -TGF-b crosstalk.
IB analysis of cell lysates (C, E, and G). ns, not statistically significant.
See also Figure S4.
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induction of mesenchymal proteins (Derynck et al., 2014). Are
Smad-dependent EMT features regulated by TSC1 and Akt? In
accordance with earlier observations (Deckers et al., 2006), up-
regulation of the mesenchymal proteins N-Cadherin and Fibro-
nectin in response to TGF-b1wasSmad4-dependent (Figure 6E).
Importantly, TSC1 deficiency strongly impaired N-cadherin and
Fibronectin induction by TGF-b1, whereas the expression of
both target genes was not inhibited by TSC2 deficiency (Fig-
ure 6E). Furthermore, TSC1, but not TSC2, deficiency abolished
Smad4-dependent morphological changes (Piek et al., 1999;
Valcourt et al., 2005) in response to TGF-b1 treatment, including
cellular transformation to a spindle-shaped morphology, loss of
intercellular contacts, and formation of stress fibers (Figures 6F
and S4B). Thus, TSC1 is not only required for TGF-b1-induced
growth arrest but also for TGF-b1-induced EMT. We next tested
whether Akt also affects TGF-b-dependent EMT in our cell
system. Depending on the physiological context, Akt1 has
been shown to promote (Bakin et al., 2000; Ju et al., 2007; Xue
et al., 2012; Zhang et al., 2012; Zhou et al., 2006) or inhibit
(Chin and Toker, 2010; Dillon et al., 2009; Hutchinson et al.,
2004; Iliopoulos et al., 2009; Irie et al., 2005; Liu et al., 2006; Mar-
oulakou et al., 2007; Yoeli-Lerner et al., 2005) EMT, migration,
and metastasis. We found that in NMuMG cells, myr-Akt1 coun-
teracted TGF-b1-induced downregulation of the epithelial mar-
ker E-cadherin (Figure 6G) and did not affect morphological
EMT changes (Figure S4C). Thus, despite its stimulating effect
on Smad2/3 phosphorylation (Figure 6C), myr-Akt did not rein-
force or accelerate TGF-b1-induced transcriptional or morpho-
logical EMT features (Figures 6G and S4C). The same stably
myr-Akt expressing cell line showed enhanced Smad-depen-
dent G1 arrest (Figure 6D), confirming that myr-Akt expression
was sufficient to trigger a physiological response. Different direct
and indirect Akt1 targets have been implicated in either the
stimulatory (Ju et al., 2007; Xue et al., 2012; Zhang et al.,
2012), or the inhibitory (Chin and Toker, 2010; Irie et al., 2005;
Liu et al., 2006; Yoeli-Lerner et al., 2005) function of Akt1 in
EMT andmetastasis. Thus, onemay hypothesize that Akt activity
concomitantly provides both stimulating and inhibiting inputs on
EMT by regulating distinct sub-populations of its substrates.
Thus, in NMuMG cells, the stimulatory input of myr-Akt1-depen-
dent Smad phosphorylation (Figure 6C) may be overridden by
inhibitory inputs, preventing the acquisition of a mesenchymal
phenotype (Figure S4C).
DISCUSSION
We identify TSC1 as a component of the TGF-b-Smad2/3
pathway that positively regulates TbR-I association with its sub-
strates Smad2/3 (Figure 3E) and thus stimulates Smad2/3 phos-
pho-activation (Figures 1A–1C, 6B, S1A, S1C, and S1D) (scheme
depicted in Figure 6H). TSC1 exerts this function independently
of TSC1-TSC2 complex activity (Figures 1A, 1B, 1D, 6B, and
S1D). In keeping with this, TSC1 (but not TSC2) is required for
both Smad-dependent growth arrest and EMT (Figures 6A, 6E,
and 6F) and thus contributes to processes underlying both the
tumor-suppressive and the pro-metastatic action of the TGF-
b-Smad pathway. Insulin-Akt promotes Smad2/3 phosphoryla-
tion in a TSC1-dependent manner (Figures 4G, 4H, 4K, and
4L), and hyperactive Akt triggers cytostatic Smad signaling to626 Developmental Cell 32, 617–630, March 9, 2015 ª2015 Elsevierinduce growth arrest (Figure 6D). Thus, TSC1 links insulin-Akt
signaling to the TGF-b-Smad2/3 pathway.
What may be the physiological function of this crosstalk? A
hyperactive PI3K-Akt axis is a serious threat for an organism,
as unrestrained Akt-dependent cell growth and proliferation
may result in tumor development (Zoncu et al., 2011). It is well
conceivable that in contexts of aberrant Akt activity, TSC1-
dependent TGF-b-Smad activation represents a rescue mecha-
nism to prevent cellular overgrowth via induction of cytostatic
target genes and growth arrest (Figures 1H, 6B,6D, S1E, S1F,
and S4A). Such a cytostatic function of Akt seems to be at
odds with Akt’s established role as a survival kinase (Hers
et al., 2011). However, several recent studies have revealed
that whereas Akt activity normally stimulates cell proliferation
and survival, aberrantly activated Akt may in contrast induce
apoptosis and cellular senescence, a state of permanent cell-cy-
cle arrest (Los et al., 2009; Minamino et al., 2004; Miyauchi et al.,
2004; Nogueira et al., 2008). We propose here that Akt-TSC1-
TGF-b crosstalk represents one molecular mechanism that ac-
counts for the cytostatic action of hyperactive Akt.
Of note, two previous studies (Conery et al., 2004; Remy
et al., 2004) have reported that Akt directly interacts with the
Smad3 protein to counteract Smad3 phospho-activation and
Smad3-mediated apoptosis, in cell types (Hep3B, Ba/F3) other
than those used in our study (NMuMG, HeLa, HEK293T). More
recently, however, Zhang et al. (2012) reported a stimulatory
function of Akt on Smad2/3 signaling in different breast can-
cer cell lines. Here, Akt phospho-activated the deubiquitylating
enzyme USP4, resulting in reduced ubiquitylation-mediated de-
gradation of TbR-I and thus enhanced Smad signaling (Zhang
et al., 2012). Moreover, in a study of Xue et al. (2012), Akt
has been shown to transcriptionally upregulate TGF-b2 in
MDCK and 4T1 cells via phospho-activation of the transcription
factor Twist1. This resulted in enhanced Smad2 signaling (Xue
et al., 2012). Importantly, in vivo evidence exists for both inhib-
itory (Duenker et al., 2005) and stimulatory (Xue et al., 2012;
Zhang et al., 2012) inputs of insulin/Akt on TGF-b-Smad
signaling. Taken together, these and our findings suggest
that multiple mechanisms of Akt-TGF-b crosstalk exist. It is
conceivable that even opposing molecular crosstalk mecha-
nisms may take place simultaneously in a cell. The net outcome
of Akt-dependent TGF-b pathway regulation, i.e., inhibition or
stimulation, would thus depend on the specific physiological
condition.
Smad signaling exerts fundamental functions during embry-
onic development. Smad2/ mice display gastrulation and
mesoderm formation defects and die before E8.5 (Heyer et al.,
1999; Nomura and Li, 1998; Waldrip et al., 1998; Weinstein
et al., 1998). Interestingly, TSC1/ mice progress normally
through gastrulation and die only at later stages of embryonic
development (embryonic day 10.5 [E10.5]–E11.5) (Kobayashi
et al., 2001). What accounts for the phenotypic differences
observed between Smad2/ and TSC1/ mice? Similar to
TSC1 (Figures 5A–5F), multiple other modulators of Smad2/3
phospho-activation reside at the early endosomes, including
SARA (Tsukazaki et al., 1998), cytoplasmic PML (cPML) (Lin
et al., 2004), endofin (Chen et al., 2007), and HGF-regulated tyro-
sine kinase substrate (Hgs/Hrs) (Miura et al., 2000). All existing
knockout mouse models of the previously mentioned SmadInc.
modulators (Komada and Soriano, 1999; Wang et al., 1998) fail
to recapitulate important features of Smad2/ mice, such as
lack of mesoderm, gastrulation defects, and early embryonic
lethality. This raises the possibility that different endosomal reg-
ulators can compensate for each other in Smad activation, which
may also explain why TSC1/ mice do not recapitulate Smad2
knockout features.
TSC1 ablation results in phenotypes that closely resemble
TSC2 mutants in different organisms (Orlova and Crino, 2010).
This, together with the well-established TSC1-TSC2 interaction,
led to the general view that TSC1 and TSC2 act exclusively in
complex. Our results, and previous findings (Miloloza et al.,
2002), challenge the common notion that TSC1 and TSC2 are
strictly interdependent. Further evidence for separate functions
of TSC1 and TSC2 comes from microarray analyses and prote-
omic approaches, which reveal that the TSC genes trigger
substantially different cellular responses (Hengstschla¨ger et al.,
2005; Rosner et al., 2005). Interestingly, in some cancers (renal,
bladder) TSC1 mutations seem to be more prevalent, as com-
pared to TSC2 (Hornigold et al., 1999; Kucejova et al., 2011; Py-
mar et al., 2008). How can a TSC2-independent function of TSC1
be reconciled with the highly similar phenotypes of TSC1 and
TSC2 mutants? Inactivation of TSC1 or TSC2 strongly induces
mitogenic mTORC1 signaling; one may hypothesize that consti-
tutive aberrant mTORC1 activation due to severe TSC1 or TSC2
dysfunction overrides more subtle regulatory mechanisms and
might thus eventually dominate the phenotypes caused by
TSC1 or TSC2 mutations. However, when the TSCs are func-
tional, the TSC1-TGF-b crosstalk may play an important physio-
logical role particularly under conditions of active Akt signaling.
Our findings have critical implications for cancer therapy,
because drugs inhibiting Akt could have the unfavorable side ef-
fect of abrogating cytostatic TGF-b signaling. On the other hand,
mTORC1 inhibitors may exert their growth-inhibitory function in
part by activating Akt (via the NFL) and TSC1-dependent cyto-
static TGF-b signaling. This suggests that the TGF-b network
should be cautiously monitored upon treatment with PI3K, Akt,
and mTOR inhibitors, and that the contribution of the TGF-b
pathway to the treatment outcome of these drugs warrants
investigation in clinical studies.EXPERIMENTAL PROCEDURES
Cell Culture, Drug Treatments, Cloning, and Transfection
HeLa, HEK293T, and NMuMGcells were cultured according to the recommen-
dations of the American Type Culture Collection (ATCC). Cloning, transfection,
treatments, and plasmids (including those received from Addgene) are
described in detail in the Supplemental Experimental Procedures. Addgene
plasmids used in the present study were originally described in the following
publications: Cai et al. (2006); Ramaswamy et al. (1999); Tee et al. (2002);
Wrana et al. (1992); Zhang et al. (1998). C-terminally myc-tagged TSC1 full-
length and truncation constructs were a kind gift of Mark Nellist, Erasmus
MC, Rotterdam, the Netherlands, and published in Hoogeveen-Westerveld
et al. (2010).
RNA Interference and Transgenic Cell Lines
Cell lines with inducible knockdown of TSC1, TSC2, Rheb, and Raptor were
generated using the previously described doxycycline/tetracycline-sensitive
tTR-KRAB system (Wiznerowicz and Trono, 2003). Details on transduction,
knockdown induction, and target sequences of shRNA are given in the Supple-
mental Experimental Procedures.DevelNMuMG control and Smad4 knockdown cells were a kind gift from Prof.
Gerhard Christofori (University of Basel, Switzerland) and previously described
in Deckers et al. (2006).
Cell Lysate Preparation, Immunoprecipitation, Immunoblot, and
Quantitation
Cell lysis, immunoprecipitation (IP), and immunoblot (IB) analysis were
performed as described (Dalle Pezze et al., 2012). Details on lysis buffers, IB
analysis, and antibodies used in IB and IP are given in the Supplemental Exper-
imental Procedures.
Immunofluorescence, Imaging, and Quantitation
Cells were cultivated on glass coverslips in six-well tissue culture plates. Gen-
eral staining procedures were performed as described (Thedieck et al., 2013).
See Supplemental Experimental Procedures for details on staining protocols,
wide field and confocal imaging, and image analysis. Antibodies used in IF are
listed in the Supplemental Experimental Procedures (list of antibodies).
Proximity Ligation Assay
The PLA technique was performed as previously described (So¨derberg et al.,
2008). All reagents used for PLA analysis were purchased from Olink Biosci-
ence, Sweden (current distributor: Sigma-Aldrich). Experimental details and
antibodies used in PLA are described in the Supplemental Experimental
Procedures.
Propidium Iodide Staining and Flow Cytometry
Cell-cycle analysis was performed using propidium iodide staining, followed
by fluorescence-activated cell sorting analysis. For details, see the Supple-
mental Experimental Procedures.
Statistical Analysis
The following experiments involving control and TSC1/2 knockdown cells un-
der different treatments were statistically analyzed with one-way ANOVA fol-
lowed by Tukey’s Multiple comparison test (suitable for statistical comparison
of multiple experimental groups): pSmad/total Smad ratio (Figures 1B, 2B, 2E,
and 6B), nuclear localization of pSmad2/3 (Figure 1G), expression of p57Kip2
(Figure S1F), TSC1-Smad2/3 association (Figure 3B), and G1 arrest (Figures
6A and 6D). Two-tailed Student’s t test assuming unequal variances was
used for statistical analysis of TSC1-TbR-I and TbR-I-Smad2/3 interaction in
myr-Akt/empty vector transfected HeLa cells (Figures 4B and 4E), and
TSC1-EEA1 co-localization quantified by the Spearman’s correlation coeffi-
cient (see manuscript text).
p values above 0.05 were considered non-significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.devcel.2015.01.026.
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